Mastercard (MA) Offering Possible 40.85% Return Over the Next 24 Calendar Days

Mastercard's most recent trend suggests a bearish bias. One trading opportunity on Mastercard is a Bear Call Spread using a strike $280.00 short call and a strike $290.00 long call offers a potential 40.85% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $280.00 by expiration. The full premium credit of $2.90 would be kept by the premium seller. The risk of $7.10 would be incurred if the stock rose above the $290.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Mastercard is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Mastercard is bearish.

The RSI indicator is at 40.42 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Mastercard

Fintech Companies To Buy And Watch: Apple Launches New Credit Card
Fri, 20 Sep 2019 13:30:03 +0000
There are many emerging fintech companies in which to invest. Digital payment technology is changing the competitive landscape in fields like e-commerce, payment networks and banking.

MasterCard (MA) Stock Moves 0.23%: What You Should Know
Thu, 19 Sep 2019 21:45:09 +0000
MasterCard (MA) closed the most recent trading day at $275.72, moving +0.23% from the previous trading session.

Mastercard Stock Will Rise Because of Its New Business-Payments Offerings, Analyst Says
Wed, 18 Sep 2019 20:24:00 +0000
New initiatives into business-to-business payments will drive the company’s stock higher, according to MoffettNathanson analyst Lisa Ellis.

Goldman Sachs: 4 Conviction Buy Stocks To Snap Up Now
Wed, 18 Sep 2019 13:07:09 +0000
Goldman Sachs has a special rating for stocks which it holds in particularly high regard. This is called a ‘Conviction Buy’ rating. The firm’s prized list of Conviction Buy stocks reveals the stock picks that the investment bank's research team expects to outperform. That’s particularly useful for investors looking for fresh investing inspiration in the face of current market volatility. Here we take a closer look at four stocks that have made it to the firm’s list of top stock ideas. Does the rest of the Street have an equally bullish outlook on these names? Interestingly, all of the stocks covered have received only buy ratings from the Street in the last three months. So no hold or sell ratings here. Let’s take a closer look at what’s keeping analysts on-side now… Comcast Corporation Shares in this cable giant are up 37% year-to-date, and analysts believe further growth lies ahead. Ten analysts have published recent buy ratings on Comcast (CMCSA – Get Report), with Goldman Sachs’ Brett Feldman going so far as to double-upgrade CMCSA all the way from Hold to Conviction Buy. Thanks to "healthy fundamentals across its key businesses”, Feldman foresees "strong growth" over the next three years with annual earnings growth of 11%, free cash flow per share of 12% and dividends of 15%. At the same time, five-star Oppenheimer analyst Timothy Horan has just upgraded Comcast from Hold to Buy. Like Feldman, he has a $54 price target, which translates into upside potential of 16%. So what’s the reason behind his bullish transition on the stock? The analyst referred to a triple whammy of broadband strength, underestimated ad revenue, and secular cable improvements. “Fundamentals are healthy in the near-term, and we think 2020 is setting up to be a strong year.” Horan stated. “Cable margins should continue to expand as revenue mix shifts to higher margin broadband (estimated 70% adj. EBITDA margins) vs. video (estimated 20% margins).” Voya Financial IncBased in New York, Voya Financial (VOYA – Get Report) is a retirement, investment and insurance company serving over 13 million customers. On September 12, Goldman Sachs’ Alex Scott upgraded VOYA from Buy to Conviction Buy, citing three key reasons: 1) the possibility of a takeover; 2) potential upside to capital return from life redundant reserve refinancing; and 3) exposure to low interest rates more fully reflected in the valuation. Indeed, the analyst’s Street-high price target of $85 indicates substantial upside potential from current levels of 56%. Note that shares have already surged 35% year-to-date. Meanwhile Morgan Stanley’s Nigel Dally has just met up with Voya management. He left the meetings reassured of his bullish outlook on the company, reiterating his buy rating and $63 price target. The analyst stated "We continue to highlight Voya as one of the most compelling investment opportunities in the life and annuity industry following time on the road through Europe with management. Despite the somewhat disappointing second quarter earnings and lower earnings run-rate, we feel the future prospects for attractive growth and ROE expansion are stronger than what is reflected in the current stock price." Mastercard IncAll eighteen analysts covering Mastercard (MA – Get Report) rate the stock a buy right now. But Goldman Sachs has gone one step further. The firm’s James Schneider has now kept a Conviction Buy rating on Mastercard for over a year. He upgraded the stock to best idea status on September 17 2018, writing at the time that Mastercard is catalyzing the next growth horizon in business-to-business (B2B) payments. "We believe the B2B market represents the next growth horizon for the payments industry and think Mastercard is the best positioned given its multifaceted product approach," Schneider said in a research note. In fact, Goldman Sachs has calculated that B2B payments will represent a whopping $950 billion annualized opportunity for payment stocks. More recently, Schneider reiterated his MA buy rating after management reaffirmed its 2019 guidance. Following the recent earnings call, the analyst told investors that he is optimistic the stock will continue to soar. Shares are already up 46% year-to-date- while the average analyst price target indicates a further 15% upside lies ahead. Bio-Rad Laboratories According to the Street, Bio-Rad (BIO – Get Report) offers attractive exposure to Life Science Tools at a reasonable valuation. With annual sales of $2.2 billion, BIO is among the top five life science companies in the world. And now Goldman Sachs analyst Patrick Donnelly has upgraded Bio-Rad to the Conviction Buy list, citing improving execution and undervalued fundamentals. Looking forward, Donnelly is confident BIO can outperform second half guidance due to strong organic growth, easing comps, margin expansion initiatives, limited maco headwinds and capital deployment. He maintained a $400 price target- indicating 20% upside potential from current levels.In the last three months, only one other analyst has published a rating on BIO stock. That analyst is Barclays’ Jack Meehan. His buy rating comes with a $380 price target- up from $350 previously. “We continue to believe that Bio-Rad has substantial long-term opportunity ahead, and believe there is good visibility into high-teens EPS growth” comments Meehan. He made the call after Bio-Rad delivered solid 2Q19 results, with a notable EPS beat and strong operational discipline. Year-to-date, the stock has rallied 45%. Discover Wall Street’s most loved stocks with the Top Analysts’ Stocks tool

Factors Likely to Drive Mastercard's (MA) Long-Term Growth
Wed, 18 Sep 2019 12:30:12 +0000
Mastercard (MA) is well positioned for growth on the back of increasing adoption of electronic payments, use of new payment rails, and service and product expansion.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.